BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-462@pharmaconomics
DTSTAMP:20260707T030340Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:SRRK Phase 3 — apitegromab
DESCRIPTION:Phase 3 trial results for apitegromab in spinal muscular atrophy (SMA) are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm\n\nTrack it: https://pharmaconomics.com/e/462
URL:https://pharmaconomics.com/e/462
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SRRK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR